Table 4. Clinical outcomes of viral reactivation in DRESS patients Table 4. Clinical outcomes of viral reactivation in DRESS patients Table 4. Clinical outcomes of viral reactivation in DRESS patients Table 4. Clinical outcomes of viral reactivation in DRESS patients Table 4. Clinical outcomes of viral reactivation in DRESS patients Table 4. Clinical outcomes of viral reactivation in DRESS patients Table 4. Clinical outcomes of viral reactivation in DRESS patients Table 4. Clinical outcomes of viral reactivation in DRESS patients Table 4. Clinical outcomes of viral reactivation in DRESS patients Table 4. Clinical outcomes of viral reactivation in DRESS patients Table 4. Clinical outcomes of viral reactivation in DRESS patients Table 4. Clinical outcomes of viral reactivation in DRESS patients
Inpatient mortality, n(%)
Mortality in 1 year, n(%)
ICU, n(%)
Dialysis, n(%)
Dialysis, n(%)
Length of hospital stay**, Mean (SD) Length of hospital stay**, Mean (SD) Length of hospital stay**, Mean (SD)
Flares in 1 year, n(%)
Flares in 1 year, n(%)
Readmission in 1 year, n(%)
Readmission in 1 year, n(%)
Viral Reactivation
No (N=54) 5 (9.3) 5 (9.3) 6 (11.1) 5 (9.3) 5 (9.3) 14.4 (16.3) 14.4 (16.3) 14.4 (16.3) 9 (16.7) 9 (16.7) 13 (24.1) 13 (24.1)
Yes (N=39) 9 (23.1) 11 (28.2) 9 (23.1) 10 (25.6) 10 (25.6) 31.3 (47.5) 31.3 (47.5) 31.3 (47.5) 15 (38.5) 15 (38.5) 19 (48.7) 19 (48.7)
Total (N=93) 14 (15.1) 16 (17.2) 15 (16.1) 15 (16.1) 15 (16.1) 21.5 (34.0) 21.5 (34.0) 21.5 (34.0) 24 (25.8) 24 (25.8) 32 (34.4) 32 (34.4)
Unadjusted OR/IRR (95% CI)* 2.9 (0.9 to 9.6) 3.9 (1.2 to 12.2) 2.4 (0.8 to 7.4) 3.4 (1.1 to 10.9) 3.4 (1.1 to 10.9) 2.2 (1.4, 3.3) 2.2 (1.4, 3.3) 2.2 (1.4, 3.3) 3.1 (1.2 to 8.2) 3.1 (1.2 to 8.2) 1.3 (0.7 to 2.3) 1.3 (0.7 to 2.3)
p-value 0.07 0.02 0.13 0.04 0.04 <0.01 <0.01 <0.01 0.02 0.02 0.41 0.41
HHV6 Reactivation
No (N=61) 07 (11.5) 08 (13.1) 09 (14.8) 08 (13.1) 08 (13.1) 11.0 (15.0) 11.0 (15.0) 11.0 (15.0) 14 (23.0) 14 (23.0) 22 (36.1) 22 (36.1)
Yes (N=24) 6 (25.0) 7 (29.2) 6 (25.0) 6 (25.0) 6 (25.0) 18.0 (22.5) 18.0 (22.5) 18.0 (22.5) 10 (41.7) 10 (41.7) 10 (41.7) 10 (41.7)
Total (N=85) 13 (15.3) 15 (17.6) 15 (17.6) 14 (16.5) 14 (16.5) 12.0 (14.0) 12.0 (14.0) 12.0 (14.0) 24 (28.2) 24 (28.2) 32 (37.6) 32 (37.6)
Unadjusted OR/IRR (95% CI) 2.6 (0.8 to 8.7) 2.7 (0.9 to 8.6) 1.9 (0.6 to 6.2) 2.2 (0.7 to 7.2) 2.2 (0.7 to 7.2) 1.1 (0.7, 1.8) 1.1 (0.7, 1.8) 1.1 (0.7, 1.8) 2.4 (0.9 to 6.6) 2.4 (0.9 to 6.6) 1.2 (0.5 to 3.1) 1.2 (0.5 to 3.1)
p-value 0.13 0.09 0.27 0.19 0.19 0.68 0.68 0.68 0.09 0.09 0.74 0.74
CMV Reactivation
No (N=70) 7 (10.0) 8 (11.4) 8 (11.4) 8 (11.4) 8 (11.4) 10.5 (12.0) 10.5 (12.0) 10.5 (12.0) 18 (25.7) 18 (25.7) 23 (32.9) 23 (32.9)
Yes (N=19) 6 (13.6) 7 (36.8) 6 (31.6) 6 (31.6) 6 (31.6) 24.0 (30.0) 24.0 (30.0) 24.0 (30.0) 6 (31.6) 6 (31.6) 9 (47.4) 9 (47.4)
Total (N=89) 13 (14.6) 15 (16.9) 14 (15.7) 14 (15.7) 14 (15.7) 13.0 (14.0) 13.0 (14.0) 13.0 (14.0) 24 (27.0) 24 (27.0) 32 (36.0) 32 (36.0)
Unadjusted OR/IRR (95% CI) 4.2 (1.2 to 14.4) 4.5 (1.4 to 14.8) 3.6 (1.1 to 12.1) 3.6 (1.1 to 12.1) 3.6 (1.1 to 12.1) 2.6 (1.8, 4.0) 2.6 (1.8, 4.0) 2.6 (1.8, 4.0) 1.3 (0.4 to 4.0) 1.3 (0.4 to 4.0) 1.7 (0.6 to 4.8) 1.7 (0.6 to 4.8)
p-value 0.03 0.01 0.04 0.04 0.04 <0.01 <0.01 <0.01 0.61 0.61 0.30 0.30
EBV Reactivation
No (N=73) 8 (11.0) 8 (11.0) 10 (13.7) 9 (12.3) 9 (12.3) 11.0 (12.0) 11.0 (12.0) 11.0 (12.0) 20 (27.4) 20 (27.4) 23 (31.5) 23 (31.5)
Yes (N=14) 4 (28.6) 6 (42.9) 3 (21.4) 4 (28.6) 4 (28.6) 22.0 (22.0) 22.0 (22.0) 22.0 (22.0) 4 (28.6) 4 (28.6) 9 (64.3) 9 (64.3)
Total (N=87) 12 (13.8) 14 (16.1) 13 (14.9) 13 (14.9) 13 (14.9) 12.0 (15.0) 12.0 (15.0) 12.0 (15.0) 24 (27.6) 24 (27.6) 32 (36.8) 32 (36.8)
Unadjusted OR/IRR (95% CI) 3.3 (0.8 to 12.8) 6.1 (1.7 to 22.1) 1.7 (0.4 to 7.3) 2.8 (0.7 to 11.0) 2.8 (0.7 to 11.0) 1.2 (0.7, 2.1) 1.2 (0.7, 2.1) 1.2 (0.7, 2.1) 1.1 (0.3 to 3.8) 1.1 (0.3 to 3.8) 3.7 (1.1 to 12.2) 3.7 (1.1 to 12.2)
p-value 0.09 <0.01 0.46 0.13 0.13 0.53 0.53 0.53 0.93 0.93 0.03 0.03
Number of Herpesvirus reactivations Number of Herpesvirus reactivations Number of Herpesvirus reactivations Number of Herpesvirus reactivations Number of Herpesvirus reactivations
< 2 (N=78) 8 (10.3) 8 (10.3) 10 (12.8) 10 (12.8) 10 (12.8) 20.0 (36.0) 20.0 (36.0) 19 (24.4) 19 (24.4) 19 (24.4) 25 (32.1) 25 (32.1)
≥ 2 (N=15) 6 (40.0) 8 (53.3) 5 (33.3) 5 (33.3) 5 (33.3) 29.1 (19.0) 29.1 (19.0) 5 (33.3) 5 (33.3) 5 (33.3) 8 (53.3) 8 (53.3)
Total (N=93) 14 (15.1) 16 (17.2) 15 (16.1) 15 (16.1) 15 (16.1) 21.5 (34.0) 21.5 (34.0) 24 (25.8) 24 (25.8) 24 (25.8) 33 (35.5) 33 (35.5)
Unadjusted OR/IRR (95% CI) 5.8 (1.7 to 20.7) 10.0 (2.9 to 34.9) 3.4 (1.0 to 12.0) 3.4 (1.0 to 12.0) 3.4 (1.0 to 12.0) 1.5 (0.9, 2.5) 1.5 (0.9, 2.5) 1.6 (0.5 to 5.1) 1.6 (0.5 to 5.1) 1.6 (0.5 to 5.1) 2.4 (0.8 to 7.4) 2.4 (0.8 to 7.4)
p-value <0.01 <0.01 0.06 0.06 0.06 0.16 0.16 0.47 0.47 0.47 0.12 0.12
Note: **Poisson regression model was fit and associated risk is expressed as incidence rate ratio (IRR) with corresponding 95%CI. *Unadjusted OR is calculated with respect to “no viral reactivation”, Unadjusted OR is calculated with respect to “no HHV6 Reactivation”, Unadjusted OR is calculated with respect to “no CMV Reactivation”, Unadjusted OR is calculated with respect to “no EBV Reactivation”, Unadjusted OR is calculated with respect to “≤ 2 Herpesvirus reactivations”. Note: **Poisson regression model was fit and associated risk is expressed as incidence rate ratio (IRR) with corresponding 95%CI. *Unadjusted OR is calculated with respect to “no viral reactivation”, Unadjusted OR is calculated with respect to “no HHV6 Reactivation”, Unadjusted OR is calculated with respect to “no CMV Reactivation”, Unadjusted OR is calculated with respect to “no EBV Reactivation”, Unadjusted OR is calculated with respect to “≤ 2 Herpesvirus reactivations”. Note: **Poisson regression model was fit and associated risk is expressed as incidence rate ratio (IRR) with corresponding 95%CI. *Unadjusted OR is calculated with respect to “no viral reactivation”, Unadjusted OR is calculated with respect to “no HHV6 Reactivation”, Unadjusted OR is calculated with respect to “no CMV Reactivation”, Unadjusted OR is calculated with respect to “no EBV Reactivation”, Unadjusted OR is calculated with respect to “≤ 2 Herpesvirus reactivations”. Note: **Poisson regression model was fit and associated risk is expressed as incidence rate ratio (IRR) with corresponding 95%CI. *Unadjusted OR is calculated with respect to “no viral reactivation”, Unadjusted OR is calculated with respect to “no HHV6 Reactivation”, Unadjusted OR is calculated with respect to “no CMV Reactivation”, Unadjusted OR is calculated with respect to “no EBV Reactivation”, Unadjusted OR is calculated with respect to “≤ 2 Herpesvirus reactivations”. Note: **Poisson regression model was fit and associated risk is expressed as incidence rate ratio (IRR) with corresponding 95%CI. *Unadjusted OR is calculated with respect to “no viral reactivation”, Unadjusted OR is calculated with respect to “no HHV6 Reactivation”, Unadjusted OR is calculated with respect to “no CMV Reactivation”, Unadjusted OR is calculated with respect to “no EBV Reactivation”, Unadjusted OR is calculated with respect to “≤ 2 Herpesvirus reactivations”. Note: **Poisson regression model was fit and associated risk is expressed as incidence rate ratio (IRR) with corresponding 95%CI. *Unadjusted OR is calculated with respect to “no viral reactivation”, Unadjusted OR is calculated with respect to “no HHV6 Reactivation”, Unadjusted OR is calculated with respect to “no CMV Reactivation”, Unadjusted OR is calculated with respect to “no EBV Reactivation”, Unadjusted OR is calculated with respect to “≤ 2 Herpesvirus reactivations”. Note: **Poisson regression model was fit and associated risk is expressed as incidence rate ratio (IRR) with corresponding 95%CI. *Unadjusted OR is calculated with respect to “no viral reactivation”, Unadjusted OR is calculated with respect to “no HHV6 Reactivation”, Unadjusted OR is calculated with respect to “no CMV Reactivation”, Unadjusted OR is calculated with respect to “no EBV Reactivation”, Unadjusted OR is calculated with respect to “≤ 2 Herpesvirus reactivations”. Note: **Poisson regression model was fit and associated risk is expressed as incidence rate ratio (IRR) with corresponding 95%CI. *Unadjusted OR is calculated with respect to “no viral reactivation”, Unadjusted OR is calculated with respect to “no HHV6 Reactivation”, Unadjusted OR is calculated with respect to “no CMV Reactivation”, Unadjusted OR is calculated with respect to “no EBV Reactivation”, Unadjusted OR is calculated with respect to “≤ 2 Herpesvirus reactivations”. Note: **Poisson regression model was fit and associated risk is expressed as incidence rate ratio (IRR) with corresponding 95%CI. *Unadjusted OR is calculated with respect to “no viral reactivation”, Unadjusted OR is calculated with respect to “no HHV6 Reactivation”, Unadjusted OR is calculated with respect to “no CMV Reactivation”, Unadjusted OR is calculated with respect to “no EBV Reactivation”, Unadjusted OR is calculated with respect to “≤ 2 Herpesvirus reactivations”. Note: **Poisson regression model was fit and associated risk is expressed as incidence rate ratio (IRR) with corresponding 95%CI. *Unadjusted OR is calculated with respect to “no viral reactivation”, Unadjusted OR is calculated with respect to “no HHV6 Reactivation”, Unadjusted OR is calculated with respect to “no CMV Reactivation”, Unadjusted OR is calculated with respect to “no EBV Reactivation”, Unadjusted OR is calculated with respect to “≤ 2 Herpesvirus reactivations”. Note: **Poisson regression model was fit and associated risk is expressed as incidence rate ratio (IRR) with corresponding 95%CI. *Unadjusted OR is calculated with respect to “no viral reactivation”, Unadjusted OR is calculated with respect to “no HHV6 Reactivation”, Unadjusted OR is calculated with respect to “no CMV Reactivation”, Unadjusted OR is calculated with respect to “no EBV Reactivation”, Unadjusted OR is calculated with respect to “≤ 2 Herpesvirus reactivations”. Note: **Poisson regression model was fit and associated risk is expressed as incidence rate ratio (IRR) with corresponding 95%CI. *Unadjusted OR is calculated with respect to “no viral reactivation”, Unadjusted OR is calculated with respect to “no HHV6 Reactivation”, Unadjusted OR is calculated with respect to “no CMV Reactivation”, Unadjusted OR is calculated with respect to “no EBV Reactivation”, Unadjusted OR is calculated with respect to “≤ 2 Herpesvirus reactivations”. Note: **Poisson regression model was fit and associated risk is expressed as incidence rate ratio (IRR) with corresponding 95%CI. *Unadjusted OR is calculated with respect to “no viral reactivation”, Unadjusted OR is calculated with respect to “no HHV6 Reactivation”, Unadjusted OR is calculated with respect to “no CMV Reactivation”, Unadjusted OR is calculated with respect to “no EBV Reactivation”, Unadjusted OR is calculated with respect to “≤ 2 Herpesvirus reactivations”.